Abstract:Background: Accumulating evidence indicates that metabolic events profoundly modulate the progression of various diseases. The pyruvate kinases catalyze the production of pyruvate and pyruvate kinase M2 (PKM2) is a unique isoform involved in the development of tumors. In the present study, the pathological significance of PKM2 has been investigated in mice with lipopolysaccharide/D-galactosamine (LPS/D-Gal)-induced fulminant liver injury. Methods: Fulminant liver injury was induced in mice by intraperitoneal injection of LPS/D-Gal, the level of nuclear PKM2, the activity of pyruvate kinase and the content of pyruvate were determined. To investigated the significance of PKM2/ pyruvate, the PKM2 modulator TEPP-46, DASA-58 or the cell permeable ethyl pyruvate (EP) was administered and the degree of hepatocyte apoptosis and liver damage were evaluated. In addition, phospho-antibody microarray was used to identify the underlying signaling pathways. Findings: LPS/D-Gal exposure increased the nuclear level of PKM2 but decreased the activity of pyruvate kinase and the content of pyruvate. Treatment with the PKM2 modulator TEPP-46 or supplementation with ethyl pyruvate (EP) suppressed LPS/D-Gal-induced liver damage. Interestingly, post-insult administration of TEPP-46, another PKM2 modulator DASA-58 or EP also resulted in beneficial outcomes. The phospho-antibody microarray analysis found that LPS/D-Gal induced inhibitory phosphorylation of cyclin dependent kinase 1 (CDK1), which was reversed by TEPP-46, DASA-58 or EP. In addition, the therapeutic benefits of TEPP-46 or EP were blunted by the CDK1 inhibitor Ro 3306. Interpretation: Our data suggests that LPS/D-Gal exposure-induced accumulation of nuclear PKM2, decline of pyruvate and inactivation of CDK1 might be a novel metabolic mechanism underlies the development of LPS/D-Gal-induced fulminant liver injury, PKM2/pyruvate might be a promising target for the pharmacological intervention of fulminant hepatocyte damage. Funding: This work was supported by the grants from the National Natural Science Foundation of China (No. 81871606) and the grant from Science and Technology Research Program of Chongqing Municipal Education Commission (No. KJQN201900435). Declaration of Interest: None to declare. Ethical Approval: The Ethics Committee of Chongqing Medical University approved all mouse experiments.

<i>Imidacloprid</i> activates Kupffer cells pyroptosis to induce liver injury in mice via P2X7

Imidacloprid-induced lung injury in mice: Activation of the PI3K/AKT/NF-κB signaling pathway via TLR4 receptor engagement

Inhibition of Hepatic Cells Pyroptosis Attenuates CLP-induced Acute Liver Injury.

Aflatoxin B 1 -induced liver pyroptosis is mediated by disturbing the gut microbial metabolites: The roles of pipecolic acid and norepinephrine

Acute Liver Toxicity Induced by 1,1-Diphenyl-2-picryl-hydrazyl (DPPH) in ICR Mice.

Direct Inhibition of GSDMD by PEITC Reduces Hepatocyte Pyroptosis and Alleviates Acute Liver Injury in Mice

Toxicological mechanism of triptolide-induced liver injury: Caspase3-GSDME-mediated pyroptosis of Kupffer cell

Ferroptosis contribute to neonicotinoid imidacloprid-evoked pyroptosis by activating the HMGB1-RAGE/TLR4-NF-κB signaling pathway

[Inhibitive Mechanisms of Pim-3 Affecting Fulminant Hepatic Apoptosis].

Hepatotoxicity of Pyrrolizidine Alkaloid Compound Intermedine: Comparison with Other Pyrrolizidine Alkaloids and Its Toxicological Mechanism

Dibutyl phthalate induces liver fibrosis via p38MAPK/NF-κB/NLRP3-mediated pyroptosis

PM2.5 exposure aggravates acute liver injury by creating an inflammatory microenvironment through Kupffer cell

Aflatoxin B1 Enhances Pyroptosis of Hepatocytes and Activation of Kupffer Cells to Promote Liver Inflammatory Injury Via Dephosphorylation of Cyclooxygenase-2: an in Vitro, Ex Vivo and in Vivo Study

Accumulation of Nuclear PKM2 Promotes LPS/D-Gal-Induced Fulminant Liver Injury via Reduction of Pyruvate and Inactivation of CDK1

Inhibition of Macrophage Pyroptosis─A New Therapeutic Strategy to Alleviate T-2 Toxin-Induced Subacute Liver Injury by Directly Competing with the Key Target

PPARβ/δ activation protects against hepatic ischaemia-reperfusion injury

Role of IRE1α/XBP1/CHOP/NLRP3 Signalling Pathway in Neonicotinoid Imidacloprid-Induced Pancreatic Dysfunction in Rats and Antagonism of Lycopene: In Vivo and Molecular Docking Simulation Approaches

Synergistic effect of ZnO NPs and imidacloprid on liver injury in male ICR mice: Increase the bioavailability of IMI by targeting the gut microbiota

Co-exposure of Avermectin and Imidacloprid Induces DNA Damage, Pyroptosis, and Immune Dysfunction in Epithelioma Papulosum Cyprini Cells Via ROS-mediated Keap1/Nrf2/TXNIP Axis.

Activation of pregnane X receptor protects against cholestatic liver injury by inhibiting hepatocyte pyroptosis

Effect of perfluorooctane sulphonate-induced Kupffer cell activation on hepatocyte proliferation through the NF-κB/TNF-α/IL-6-dependent pathway